Baroreflex activation therapy with the <scp>Barostim</scp> ™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials

An IPD meta-analysis suggests that BAT improves exercise capacity, NYHA class, and QoL in HFrEF patients receiving GDMT. These clinically meaningful improvements were consistent across the range of patients studies. BAT was also associated with an improvement in NT-proBNP in subjects with a lower baseline NT-proBNP.